Qin Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qin Zhou has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Beatrice S. Knudsen
University of Utah
6 shared publications - Wei Zhang
Biorepository and Molecular Pathology Core, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah; Department of Pathology, University of Utah, Salt Lake City, Utah
6 shared publications - Adam Mitchell Spivak
Division of Infectious Diseases, Department of Internal Medicine, Huntsman Cancer Institute – University of Utah, Salt Lake City, Utah
5 shared publications - Alex C. Soupir
Moffitt Cancer Center
5 shared publications - Anna E. Coghill
Cancer Epidemiology Program, Division of Population Sciences, H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA
5 shared publications - Carlos Moran Segura
Advanced Analytical and Digital Laboratory, Moffitt Cancer Center, Tampa, Florida
5 shared publications
Latest Publications
- 24 September 2025
- Published by Elsevier in Laboratory Investigation
- Vol. 105 (12) , 104246
Comparison of QuPath and HALO Platforms for Analysis of the Tumor Microenvironment in Prostate Cancer
- 24 September 2025
- Published by Elsevier in Laboratory Investigation
- Vol. 105 (12) , 104246
Comparison of QuPath and HALO Platforms for Analysis of the Tumor Microenvironment in Prostate Cancer
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Human Immunodeficiency Virus–Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers
Supplemental Table 2: Number of Tumor Samples, and Number (%) Individual Patients, with Tissue Staining Results Available, by Immune Marker and Cancer Type.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Human Immunodeficiency Virus–Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers
Supplemental Table 2: Number of Tumor Samples, and Number (%) Individual Patients, with Tissue Staining Results Available, by Immune Marker and Cancer Type.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Human Immunodeficiency Virus–Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers
Supplemental Figure 1: Percentage of tumor cells staining positive for immune markers, and age and race-adjusted associations (ORs [95% CI]) between tumor immune marker staining abundance and patient HIV status, by cancer type. All immune markers associations are shown.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Human Immunodeficiency Virus–Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers
Supplemental Figure 1: Percentage of tumor cells staining positive for immune markers, and age and race-adjusted associations (ORs [95% CI]) between tumor immune marker staining abundance and patient HIV status, by cancer type. All immune markers associations are shown.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Human Immunodeficiency Virus–Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers
Supplemental Table 1: Number of Study Specimens by HIV Status, Cancer Type, and Source.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Human Immunodeficiency Virus–Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers
Supplemental Table 1: Number of Study Specimens by HIV Status, Cancer Type, and Source.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Data from Human Immunodeficiency Virus–Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers
Background:Cancer outcomes in people living with human immunodeficiency virus (PWH) may be driven in part by a distinct tumor microenvironment (TME) for cancers that develop in the setting of persistent immune dysfunction.Methods:Tumor samples from PWH were retrospectively obtained from the AIDS Cancer Specimen Resource, Moffitt Cancer Center, and Huntsman Cancer Institute. Staining of 22 different tumor immune markers was compared between PWH and cancer and patients diagnosed with the same cancer type but without human immunodeficiency virus.Results:A total of 292 samples were analyzed, with 51 samples obtained from PWH (lung cancer = 17; breast cancer = 14; and prostate cancer = 20). Cells positive for PD-1 were observed more frequently in PWH and lung cancer [OR, 1.88; 95% confidence interval (CI), 1.02–3.45], whereas CD11b+ cells were observed less frequently (OR, 0.4; 95% CI, 0.17–0.93). Three immune markers showed higher abundance in PWH and breast cancer, including PD-L1 (OR, 3.24; 95% CI, 1.52–6.91), CD14 (OR, 3.37; 95% CI, 1.14–10.0), and FOXP3 (OR, 1.91; 95% CI, 1.03–3.53). In PWH and prostate cancer, the abundance of five immune markers was higher, including PD-L1 (OR, 5.94; 95% CI, 3.77–9.34), whereas three markers had lower abundance including CD14 (OR, 0.40; 95% CI, 0.22–0.74), as well as CD16 and CD11c.Conclusions:This pilot study showed that differences in the TME exist for PWH diagnosed with age-related non-AIDS–defining cancers. Future work evaluating TME differences in relation to clinical endpoints is needed.Impact:Findings are consistent with the hypothesis of altered tumorigenesis for cancers developing in an environment of immunosuppression.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Human Immunodeficiency Virus–Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers
Background:Cancer outcomes in people living with human immunodeficiency virus (PWH) may be driven in part by a distinct tumor microenvironment (TME) for cancers that develop in the setting of persistent immune dysfunction.Methods:Tumor samples from PWH were retrospectively obtained from the AIDS Cancer Specimen Resource, Moffitt Cancer Center, and Huntsman Cancer Institute. Staining of 22 different tumor immune markers was compared between PWH and cancer and patients diagnosed with the same cancer type but without human immunodeficiency virus.Results:A total of 292 samples were analyzed, with 51 samples obtained from PWH (lung cancer = 17; breast cancer = 14; and prostate cancer = 20). Cells positive for PD-1 were observed more frequently in PWH and lung cancer [OR, 1.88; 95% confidence interval (CI), 1.02–3.45], whereas CD11b+ cells were observed less frequently (OR, 0.4; 95% CI, 0.17–0.93). Three immune markers showed higher abundance in PWH and breast cancer, including PD-L1 (OR, 3.24; 95% CI, 1.52–6.91), CD14 (OR, 3.37; 95% CI, 1.14–10.0), and FOXP3 (OR, 1.91; 95% CI, 1.03–3.53). In PWH and prostate cancer, the abundance of five immune markers was higher, including PD-L1 (OR, 5.94; 95% CI, 3.77–9.34), whereas three markers had lower abundance including CD14 (OR, 0.40; 95% CI, 0.22–0.74), as well as CD16 and CD11c.Conclusions:This pilot study showed that differences in the TME exist for PWH diagnosed with age-related non-AIDS–defining cancers. Future work evaluating TME differences in relation to clinical endpoints is needed.Impact:Findings are consistent with the hypothesis of altered tumorigenesis for cancers developing in an environment of immunosuppression.
- 4 April 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (6) , 860-867
Human Immunodeficiency Virus–Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers
Background: Cancer outcomes in people living with human immunodeficiency virus (PWH) may be driven in part by a distinct tumor microenvironment (TME) for cancers that develop in the setting of persistent immune dysfunction. Methods: Tumor samples from PWH were retrospectively obtained from the AIDS Cancer Specimen Resource, Moffitt Cancer Center, and Huntsman Cancer Institute. Staining of 22 different tumor immune markers was compared between PWH and cancer and patients diagnosed with the same cancer type but without human immunodeficiency virus. Results: A total of 292 samples were analyzed, with 51 samples obtained from PWH (lung cancer = 17; breast cancer = 14; and prostate cancer = 20). Cells positive for PD-1 were observed more frequently in PWH and lung cancer [OR, 1.88; 95% confidence interval (CI), 1.02–3.45], whereas CD11b+ cells were observed less frequently (OR, 0.4; 95% CI, 0.17–0.93). Three immune markers showed higher abundance in PWH and breast cancer, including PD-L1 (OR, 3.24; 95% CI, 1.52–6.91), CD14 (OR, 3.37; 95% CI, 1.14–10.0), and FOXP3 (OR, 1.91; 95% CI, 1.03–3.53). In PWH and prostate cancer, the abundance of five immune markers was higher, including PD-L1 (OR, 5.94; 95% CI, 3.77–9.34), whereas three markers had lower abundance including CD14 (OR, 0.40; 95% CI, 0.22–0.74), as well as CD16 and CD11c. Conclusions: This pilot study showed that differences in the TME exist for PWH diagnosed with age-related non-AIDS–defining cancers. Future work evaluating TME differences in relation to clinical endpoints is needed. Impact: Findings are consistent with the hypothesis of altered tumorigenesis for cancers developing in an environment of immunosuppression.
- 4 April 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (6) , 860-867
Human Immunodeficiency Virus–Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers
Background: Cancer outcomes in people living with human immunodeficiency virus (PWH) may be driven in part by a distinct tumor microenvironment (TME) for cancers that develop in the setting of persistent immune dysfunction. Methods: Tumor samples from PWH were retrospectively obtained from the AIDS Cancer Specimen Resource, Moffitt Cancer Center, and Huntsman Cancer Institute. Staining of 22 different tumor immune markers was compared between PWH and cancer and patients diagnosed with the same cancer type but without human immunodeficiency virus. Results: A total of 292 samples were analyzed, with 51 samples obtained from PWH (lung cancer = 17; breast cancer = 14; and prostate cancer = 20). Cells positive for PD-1 were observed more frequently in PWH and lung cancer [OR, 1.88; 95% confidence interval (CI), 1.02–3.45], whereas CD11b+ cells were observed less frequently (OR, 0.4; 95% CI, 0.17–0.93). Three immune markers showed higher abundance in PWH and breast cancer, including PD-L1 (OR, 3.24; 95% CI, 1.52–6.91), CD14 (OR, 3.37; 95% CI, 1.14–10.0), and FOXP3 (OR, 1.91; 95% CI, 1.03–3.53). In PWH and prostate cancer, the abundance of five immune markers was higher, including PD-L1 (OR, 5.94; 95% CI, 3.77–9.34), whereas three markers had lower abundance including CD14 (OR, 0.40; 95% CI, 0.22–0.74), as well as CD16 and CD11c. Conclusions: This pilot study showed that differences in the TME exist for PWH diagnosed with age-related non-AIDS–defining cancers. Future work evaluating TME differences in relation to clinical endpoints is needed. Impact: Findings are consistent with the hypothesis of altered tumorigenesis for cancers developing in an environment of immunosuppression.